Prime Inks Trio of Value-Based Pacts for Migraine Drugs
In recent weeks, Prime Therapeutics LLC has entered into not one, not two, but three value-based contracts with drug manufacturers for a trio of migraine medicines. The PBM owned by 18 Blue Cross and Blue Shield plans tells AIS Health that it identified migraine treatments as a key target for value-based pacts — which tie reimbursement to outcomes and costs — because of how the market for such drugs is shaping up.
“Prime focused on the migraine class because there were new opportunities to bring value associated with both new chronic and acute migraine [drugs] to the class, more expensive than existing therapeutics,” says Kelly McGrail-Pokuta, vice president of trade relations and strategy and chief trade relations officer at Prime. “With new products there is no real-world evidence, so by implementing value-based contracts, Prime and the manufacturers are given the opportunity to look at data.”